BTIG analyst Ryan Zimmerman maintained a Buy rating on Stryker Corporation (SYK) today and set a price target of $219. The company’s shares closed on Friday at $206.40, close to its 52-week high of $210.85.
According to TipRanks.com, Zimmerman is a top 100 analyst with an average return of 37.3% and a 66.4% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and OrthoPediatrics Corp.
Stryker Corporation has an analyst consensus of Moderate Buy, with a price target consensus of $208.73, implying a 1.1% upside from current levels. In a report issued on July 2, Wells Fargo also reiterated a Buy rating on the stock with a $228 price target.
See today’s analyst top recommended stocks >>
Based on Stryker Corporation’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $3.52 billion and net profit of $412 million. In comparison, last year the company earned revenue of $3.32 billion and had a net profit of $452 million.
Based on the recent corporate insider activity of 61 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Stryker Corp. engages in providing medical technology products and services. It operates through the following segments: Orthopaedics, MedSurg and Neurotechnology and Spine. The Orthopaedics segment provides reconstructive and trauma implant systems.
